Early Skin Inflammatory Biomarker is Predictive of Development and Persistence of Atopic Dermatitis in Infants

The STOP AD study, a randomized, open-label trial evaluating the effect of short-term (first four postnatal days to 8 weeks) skin barrier protection using AVEENO ® Dermexa Fast& Long-Lasting Balm in infants with a parent with allergic disease, demonstrated decreased cumulative incidence and decreased prevalence of AD at 12 months of age.

https://www.jacionline.org/article/S0091-6749(24)00234-3/abstract?rss=yes

Source: Journal of Allergy and Clinical Immunology - March 7, 2024 Category: Allergy & Immunology Authors: Georgios N. Stamatas, Takahiro Sato, Carol N í Chaoimh, Thierry Oddos, Richard Insel, Jonathan O’B. Hourihane, Alan D. Irvine Source Type: research